MK-2048

MK-2048は、インテグラーゼ(IN)のための第二世代のインテグラーゼ阻害剤と2.6nMと1.5nMのIC50によるINR263Kです。

目録号S2765
価格 在庫  
USD 340 In stock
USD 466 In stock
USD 630 In stock

MK-2048 化学構造
分子量: 461.87

品質と確認

Quality Control & MSDS

製品情報

  • Compare Integrase Inhibitors
    Integrase阻害剤を比較
  • 研究分野

製品の説明

生物活性

情報 MK-2048は、インテグラーゼ(IN)のための第二世代のインテグラーゼ阻害剤と2.6nMと1.5nMのIC50によるINR263Kです。
目標 IN INR263K
IC50 2.6 nM 1.5 nM [1]
In vitro試験 MK-2048 inhibits subtype B and subtype C integrase activities with IC50 of 75 nM and 80 nM, respectively. Disintegration is prevented by high concentrations of MK-2048 to a comparable extent with both subtype B and C enzymes. Mutation at the site of R263K slightly increases integrase susceptibility to MK-2048. G118R translates into a decrease in integrase activity and confers resistance to MK-2048. [2] MK-2048 inhibits S217H intasome with an IC50 of 900 nM. By contrast, MK2048 remains fully active against the N224H intasome with an IC50 of 25 nM. MK2048 displays substantially lower dissociation rates compared with raltegravir, another integrase inhibitor. [3] The subsequent selection of E138K partially restores replication capacity to approximately 13% of wt levels and increased resistance to MK-2048 to approximately 8-fold. MK-2048 is active against viruses resistant to RAL and EVG. Exposure to MK-2048 leads to the selection of G118R as a possible novel resistance mutation after 19 weeks. Continued pressure with MK-2048 subsequently leads to an additional substitution after 29 weeks at position E138K, within the IN gene. Although the G118R mutation alone confers only slight resistance to MK-2048 but not to RAL or EVG, its presence arouses a dramatic reduction in viral replication capacity compared to wild-type NL4-3. E138K both partially restores viral replication capacity and also contributes to increased levels of resistance against MK-2048. [4]
In vivo試験
臨床試験
特集

推薦された実験操作 (公開の文献だけ)

細胞アッセイ: [4]

細胞系 PM1 cells
濃度 0.0256 nM to 2 μM
処理時間 72 hours
方法 A total of 7.5×104 PM1 cells per well are infected with clonal NL4-3 virus containing the integrase mutations G118R, E138K, or G118R and E138K or with wild-type viruses (45 ng p24 virus per well) by spinoculation at 1,200 × g for 2 hours at 37 °C. Cells are washed twice to remove unbound virus and then resuspends in RPMI growth medium alone or containing various concentrations of MK-2048, ranging between 0.0256 nM and 2 μM. Experiments is performed, each in duplicate. Supernatant reverse transcriptase (RT) activity is measured at 72 hours postinfection as an indicator of virus replication. Data are normalized based on uninfected and no-drug controls included in each experiment. Viral replication capacity is determined in PM1 cells using the same methodology as that used to determine EC50s, by comparing levels of supernatant RT activity of each mutant virus to those of wild-type virus in the absence of MK-2048.

Conversion of different model animals based on BSA

SpeciesWeight (kg)Body Surface Area (m2)Km factor
Baboon120.620
Dog100.520
Monkey30.2412
Rabbit1.80.1512
Guinea pig0.40.058
Rat0.150.0256
Hamster0.080.025
Mouse0.020.0073
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

Value based on data from FDA Draft Guidelines: Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. (2002) Estimating the safe starting dose in clinical trials for therapeutics in adult healthy volunteers, U.S. Food and Drug Administration, Rockville, Maryland, USA.

For example, to convert the dose of resveratrol used in a mouse (22.4 mg/kg) to a dose based on surface area for rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download MK-2048 SDF
分子量 461.87
化学式

C21H21ClFN5O4

CAS No. 869901-69-9
保管 2年-20℃
6月-80℃in DMSO
別名
溶解度 (25°C) * In vitro DMSO 9 mg/mL (19 mM)
<1 mg/mL (<1 mM)
エタノール <1 mg/mL (<1 mM)
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 Pyrazino[1',2':1,5]pyrrolo[2,3-d]pyridazine-4-carboxamide, 2-[(3-chloro-4-fluorophenyl)methyl]-8-ethyl-1,2,6,7,8,9-hexahydro-10-hydroxy-N,6-dimethyl-1,9-dioxo-, (6S)-

研究分野

技術サポート&よくある質問(FAQ)

顧客がするかもしれない質問に対する答えは、指示を取り扱っている阻害剤で見つかります。話題は、貯蔵液(阻害剤と特別な注意を細胞ベースの分析法と動物のために必要とする問題を保存することは実験します)を準備する方法を含みます。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の問い合わせをするならば、メッセージを残してください。

* 必須

Related インテグラーゼ 阻害剤

  • Rilpivirine

    Rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI), and used to treat HIV-1 infection.

  • Elvitegravir (GS-9137, JTK-303)

    Elvitegravir (GS-9137, JTK-303)は不全ウイルス統合酵素阻害剤、HIV-1IIIB、HIV-2EHOとHIV-2RODに作用する時、IC50がそれぞれ0.7、2.8と1.4nMになる。

  • Raltegravir (MK-0518)

    Raltegravir (MK-0518)はwtのための強力なインテグラーゼ(中で)ふさ移動阻害剤です、そして、S217Qは泡立つウイルス(PFV)の中で原型を作ります。 IC50 がそれぞれ 90 nM と 40 nMです。

    Features:Raltegravir 是第一个被批准的人类免疫缺陷病毒1型(HIV-1)整合酶抑制剂。

  • BMS-707035

    BMS-707035は、特定のHIV-Iインテグラーゼ(IN)阻害剤で、IC50 が15 nMになる。

    Features:BMS-707035是有效的特定HIV整合酶(IN)可逆抑制剂。

  • Dolutegravir (GSK1349572)

    Dolutegravir (GSK1349572)は、2.7nMのIC50による次世代で2-金属結合性HIVインテグラーゼふさ移動阻害剤です。

    Features:S/GSK1349572 (GSK1349572) is a next-generation and two-metal-binding HIV integrase strand transfer inhibitor.

  • Maraviroc

    Maraviroc は、MIP-1α、MIP-1βとRANTESのケモカイン受容体CCR5阻害剤で、IC50 がそれぞれ 3.3 nM、7.2 nM と 5.2 nMです。

  • Tenofovir Disoproxil Fumarate

    Tenofovir disoproxil fumarate belongs to nucleotide analogue reverse transcriptase inhibitors (nRTIs).

  • Emtricitabine

    Emtricitabine is a nucleoside reverse transcriptase inhibitor with an IC50 of 27.7 μM.

最近見られたアイテム

Tags: MK-2048を買う | MK-2048供給者 | MK-2048を購入する | MK-2048費用 | MK-2048生産者 | オーダーMK-2048 | MK-2048代理店
お問い合わせ